Summitry LLC Increases Position in Haleon plc (NYSE:HLN)

Summitry LLC lifted its position in Haleon plc (NYSE:HLN) by 22.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,787 shares of the company’s stock after acquiring an additional 7,795 shares during the period. Summitry LLC’s holdings in Haleon were worth $399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HLN. Addison Advisors LLC increased its holdings in shares of Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after purchasing an additional 1,106 shares during the period. Synovus Financial Corp increased its holdings in Haleon by 0.8% in the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after buying an additional 1,216 shares during the period. Haverford Trust Co increased its holdings in Haleon by 5.0% in the 4th quarter. Haverford Trust Co now owns 25,842 shares of the company’s stock worth $247,000 after buying an additional 1,233 shares during the period. Greenleaf Trust raised its position in Haleon by 8.4% during the 4th quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock worth $164,000 after buying an additional 1,333 shares during the last quarter. Finally, Baron Wealth Management LLC lifted its stake in Haleon by 4.3% during the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after acquiring an additional 1,381 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HLN. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Finally, Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.95.

Haleon Price Performance

NYSE:HLN opened at $10.05 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 52 week low of $7.99 and a 52 week high of $10.80. The stock’s 50-day moving average price is $9.89 and its 200-day moving average price is $9.88. The stock has a market capitalization of $45.50 billion, a PE ratio of 29.56, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, equities analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. Haleon’s payout ratio is presently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.